Object: Acute myocardial infarction (AMI) is a serious cardiovascular disease for which there are still no effective therapeutic options available, and melanoma-associated antigen-A13 (Magea13), a member of the MAGE superfamily, has an unknown role in AMI. This study aims to investigate the potential role and molecular mechanisms of Magea13 in myocardial injury associated with AMI through in vivo and in vitro experiments.
Methods: Firstly, differentially expressed genes (DEGs) and signaling pathways were screened by RNA sequencing. Cardiac-specific Magea13 overexpression was achieved with the adeno-associated virus type 9 serotype system. Subsequently, these rats underwent left anterior descending coronary artery (LAD) ligation, followed by histopathological examination, biochemical assay, and Western blot analysis to evaluate the efficacy and feasibility of Magea13 in AMI. Meanwhile, the Magea13-overexpressing rat cardiomyocyte cell line (H9c2) was also subjected to hypoxia-glucose deficiency/reperfusion to mimic AMI injury to further validate its effects in vitro.
Results: The cardiomyocyte-specific overexpression of Magea13 was observed to attenuate myocardial injury in rats with acute myocardial infarction. Furthermore, Magea13 overexpression was demonstrated to attenuate OGD/R-induced H9c2 cell injury. Mechanistic studies have suggested that the protective effect of Magea13 may be mediated through the cAMP-PKA pathway.
Conclusion: Magea13 has been demonstrated to offer protection against AMI myocardial injury through the cAMP-PKA signaling pathway and is therefore a promising therapeutic and predictive target for AMI myocardial injury.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10495-025-02078-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): a small animal acute myocardial infarction randomized-controlled multicenter study on the effect of ischemic preconditioning.
Basic Res Cardiol
March 2025
Cardiovascular and Metabolic Disorders Programme, Duke-NUS Medical School, 8 College Road, Singapore, Singapore.
Although many cardioprotective interventions have been shown to limit infarct size (IS), in preclinical animal studies of acute myocardial ischemia/reperfusion injury (IRI), their clinical translation to patient benefit has been largely disappointing. A major factor is the lack of rigor and reproducibility in the preclinical studies. To address this, we have established the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) small animal multisite acute myocardial infarction (AMI) network, with centralized randomization and blinded core laboratory IS analysis, and have validated the network using ischemic preconditioning (IPC).
View Article and Find Full Text PDFEnhanced FGF21 Delivery via Neutrophil-Membrane-Coated Nanoparticles Improves Therapeutic Efficacy for Myocardial Ischemia-Reperfusion Injury.
Nanomaterials (Basel)
February 2025
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Acute myocardial infarction, a leading cause of death globally, is often associated with cardiometabolic disorders such as atherosclerosis and metabolic syndrome. Metabolic treatment of these disorders can improve cardiac outcomes, as exemplified by the GLP-1 agonist semaglutide. Fibroblast growth factor 21 (FGF21), a novel metabolic regulator, plays pivotal roles in lipid mobilization and energy conversion, reducing lipotoxicity, inflammation, mitochondrial health, and subsequent tissue damage in organs such as the liver, pancreas, and heart.
View Article and Find Full Text PDFCase Report: Fatal atrioesophageal fistula following atrial fibrillation ablation-critical reflections on prevention.
Front Cardiovasc Med
February 2025
Department of Radiology, Ningbo No.2 Hospital, Ningbo, China.
Radiofrequency ablation (RFA) is an important therapeutic modality for atrial fibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. However, post-procedural complications may arise, influenced by anatomical positioning and the intensity of ablation energy, with atrioesophageal fistula (AEF) being particularly rare yet severe. This case report describes a unique instance of a patient developing AEF following AF ablation, accompanied by ischemic stroke and myocardial infarction.
View Article and Find Full Text PDFTakotsubo Cardiomyopathy: A Consequence of Blunt Chest Trauma.
Cureus
February 2025
Emergency Medicine, Duke Lifepoint Conemaugh Memorial Medical Center, Johnstown, USA.
Takotsubo cardiomyopathy (TTC), also known as stress-induced cardiomyopathy or "broken heart syndrome," is a transient form of myocardial dysfunction often triggered by emotional or physical stress. While typically associated with emotional distress and possible physical stress, TTC has rarely been reported in the context of physical trauma, including blunt chest injuries. This case report describes a novel instance of TTC in an 84-year-old woman who developed the condition following a motor vehicle accident, resulting in blunt chest trauma.
View Article and Find Full Text PDFComparing myocardial injury patterns and outcomes in cardiac magnetic resonance imaging between COVID-19- and non-COVID-19-related myocarditis.
Pol J Radiol
January 2025
Department of Cardiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: Despite the low incidence of COVID myocarditis, its influence on outcomes is substantial. The pivotal role of cardiac magnetic resonance (CMR) in diagnosing myocarditis is considered to be associated with disease prognosis. The primary objective of this study was to conduct a comparative analysis of myocardial injury patterns, CMR pathologic features, outcomes, and their correlation with CMR findings in COVID- and non-COVID-related myocarditis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!